Reichmann H
Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden.
Nervenarzt. 2005 Dec;76(12):1547-57; quiz 1558. doi: 10.1007/s00115-005-2009-3.
In general, therapy for Parkinson's disease is dominated by dopamine agonists (DA) in younger patients and levodopa in older patients with comorbidities. Single or combined treatment with DA should be used as long as possible to avoid levodopa and associated complications. About 30% of our patients respond to DA monotherapy and tolerate it for quite a long time. It is important to sustain patient confidence. Although parkinsonism is an insidious disease of unknown cause resulting in destruction of important dopaminergic neurons, no other neurodegenerative disease can be treated as successfully.
一般来说，帕金森病的治疗在年轻患者中以多巴胺激动剂（DA）为主，而在患有合并症的老年患者中以左旋多巴为主。应尽可能长时间使用DA进行单一或联合治疗，以避免使用左旋多巴及其相关并发症。我们约30%的患者对DA单药治疗有反应，并能耐受较长时间。维持患者的信心很重要。虽然帕金森病是一种病因不明的隐匿性疾病，会导致重要的多巴胺能神经元受损，但没有其他神经退行性疾病能得到如此成功的治疗。
